National Health (Price and Special Patient Contribution) Amendment Determination 2021 (No. 7) (Cth)

PB 127 of 2021

National Health (Price and Special Patient Contribution) Amendment Determination 2021 (No. 7)

I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make the following Determination.

Dated               29 November 2021                 

NIKOLAI TSYGANOV

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Schedules................................................................................................................................. 1

Schedule 1—Amendments  2

National Health (Price and Special Patient Contribution) Determination 2021 (PB 35 of 2021) 2

1  Name

This instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2021 (No. 7).

This instrument may also be cited as PB 127 of 2021.

2  Commencement

(1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1.  The whole of this instrument	1 December 2021.

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

This instrument is made under section 85B of the National Health Act 1953.

4  Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Price and Special Patient Contribution) Determination 2021 (PB 35 of 2021)

1  Schedule 1, entry for Doxycycline

Omit

Doxycycline	Capsule 100 mg (as hyclate) (containing enteric coated pellets)	Oral	Doryx	7	1.36	4.11
Mayne Pharma Doxycycline	7	1.36	2.79
Doryx	21	‑	12.45
Mayne Pharma Doxycycline	21	‑	7.07
Capsule 50 mg (as hyclate) (containing enteric coated pellets)	Oral	Doryx	25	2.17	6.83
Mayne Pharma Doxycycline	25	2.17	4.58

Substitute

Doxycycline	Capsule 50 mg (as hyclate) (containing enteric coated pellets)	Oral	Doryx	25	2.17	6.83
Mayne Pharma Doxycycline	25	2.17	4.58
Capsule 100 mg (as hyclate) (containing enteric coated pellets)	Oral	Doryx	7	1.36	4.11
Mayne Pharma Doxycycline	7	1.36	2.79
Mayne Pharma Doxycycline	21	‑	7.07

2  Schedule 1, omit entry for Dutasteride

3  Schedule 1, entry for Dutasteride with tamsulosin

omit from the column headed “Claimed Price”:   19.62   substitute:        19.90

4  Schedule 1, entry for Ezetimibe

omit from the column headed “Claimed Price”:   12.04   substitute:        12.73

5  Schedule 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium)

omit from the column headed “Claimed Price”:   13.11   substitute:        14.32

6  Schedule 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium)

omit from the column headed “Claimed Price”:   14.59   substitute:        15.77

7  Schedule 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium)

omit from the column headed “Claimed Price”:   14.30   substitute:        15.47

8  Schedule 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium)

omit from the column headed “Claimed Price”:   15.26   substitute:        16.41

9  Schedule 1, entry for Metoprolol

Omit

Metoprolol	Tablet containing metoprolol tartrate 50 mg	Oral	Betaloc	100	1.77	11.52
Lopresor 50	100	1.77	3.44
Tablet containing metoprolol tartrate 100 mg	Oral	Betaloc	60	2.26	10.16
Lopresor 100	60	2.26	3.93

Substitute

Metoprolol	Tablet containing metoprolol tartrate 50 mg	Oral	Betaloc	100	1.77	11.52
Lopresor 50	100	1.77	3.44
Tablet containing metoprolol tartrate 100 mg	Oral	Betaloc	60	2.26	12.02
Lopresor 100	60	2.26	3.93

10  Schedule 1, entry for Piroxicam

Omit

Piroxicam	Capsule 10 mg	Oral	Feldene	50	4.68	12.12
Capsule 20 mg	Oral	Feldene	25	4.45	11.89
Dispersible tablet 20 mg	Oral	Feldene‑D	25	4.45	11.89

Insert

Piroxicam	Capsule 20 mg	Oral	Feldene	25	4.45	11.89
Dispersible tablet 20 mg	Oral	Feldene‑D	25	4.45	11.89

11  Schedule 1, entry for Salbutamol

Omit

Salbutamol	Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20	Inhalation	Ventolin Nebules	1	2.48	4.04
Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30	Inhalation	Asmol 2.5 uni‑dose	1	3.72	3.95
Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 20	Inhalation	Ventolin Nebules	1	2.61	4.16
Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30	Inhalation	Asmol 5 uni‑dose	1	3.92	4.15
Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC‑free formulation)	Inhalation by mouth	Ventolin CFC‑free	1	3.90	5.60
Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation)	Inhalation by mouth	Asmol CFC‑Free with dose counter	1	4.49	6.82
Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation)	Inhalation by mouth	Ventolin CFC‑Free with dose counter	1	4.49	6.82

Insert

Salbutamol	Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20	Inhalation	Ventolin Nebules	1	2.48	4.04
Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30	Inhalation	Asmol 2.5 uni‑dose	1	3.72	3.95
Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 20	Inhalation	Ventolin Nebules	1	2.61	4.16
Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30	Inhalation	Asmol 5 uni‑dose	1	3.92	4.15
Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation)	Inhalation by mouth	Asmol CFC‑Free with dose counter	1	4.49	6.82
Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation)	Inhalation by mouth	Ventolin CFC‑Free with dose counter	1	4.49	6.82